BTK and leukemia: SYK is of particular interest as a therapeutic target in leukemia and lymphoma as it plays a central role in activation of downstream kinases both via the BTK pathway and through its ability to directly phosphorylate and activate PI3K resulting in formation of second messenger PIP3 from PIP2 [40, 41].